88%Confidence
0Views
FDASource
2026-03-11Date
Summary
Recall of Adbry autoinjectors by LEO Pharma due to wool fiber contamination is a specific sterility issue affecting a high-value biologic for atopic dermatitis. While limited to one lot, it highlights supply chain vulnerabilities for injectable products.
Actionable: Confirm with LEO Pharma the lot numbers affected and ensure healthcare providers check inventory to remove any contaminated units.
AI Confidence: 88%
Data Points
firmLEO PHARMA INC
classificationClass II
statusOngoing
distributionNationwide in the USA
productAdbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single do
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now